Submission of financial results for the quarter ended 30th September 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astal Laboratories reported revenue from operations of Rs 3,751.64 lakhs for Q2 FY26, up sharply from Rs 1,315.98 lakhs in Q2 FY25, driven by its Bulk Drugs/APIs business. Total income for the half year rose to Rs 6,293.18 lakhs versus Rs 2,633.97 lakhs in H1 FY25, roughly a 139% jump. Profit after tax for the quarter stood at Rs 258.26 lakhs (vs Rs 200.29 lakhs, up ~29% YoY) and H1 PAT was Rs 467.22 lakhs (vs Rs 369.20 lakhs, up ~27%). Basic EPS for the quarter was Rs 2.40. The auditor (Sathuluri & Co) issued an unmodified limited review report with no qualifications.
Strong top-line growth and rising profits are positive for shareholders, but operating cash flow turned negative at Rs (164.10) lakhs in H1 FY26 and margins compressed sharply, signalling that profitability gains lag the revenue surge. Watch working capital and cash conversion in coming quarters.